Los mejores gastroenterólogos de Diagnóstico integral de Patología Colorrectal — TOP-51 médicos

UNIVERSITY

Ankara University Faculty of Medicine 

UNIVERSITY WHERE HE TAKES EXPERTISE

Göztepe Training and Research Hospital General Surgery

CONGRESSES ATTENDED

National Endoscopic Laparoscopic Surgery Congress

World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension

Bariatric and Metabolic Surgery Congress

Cerrahpaşa Surgery Meetings Turkish Bariatric Surgery Association

PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

• Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
• Role: Subinvestigator

2. PFİZER

• Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
• Role: Subinvestigator

3. RECITE - AMGEN

• Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
• Role: Subinvestigator

4. NAVIGATE - BAYER

• Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Role: Subinvestigator

5. RUBY - Tesaro (PRA)

• Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
• Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

• Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
• Role: Subinvestigator

7. ASTRA ZENECA

• Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
• Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

• Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
• Role: Subinvestigator
•  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
• Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
• Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

• Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
• Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

• Authors: Paksoy, Nail, et al.
• Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

• Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
• Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

• Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
• Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

• Authors: HAS SIMSEK, Duygu, et al.
• Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

• Authors: FERHATOGLU, Ferhat, et al.
• Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

• Authors: GÜRBÜZ, Mustafa, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

• Authors: AY, Seval, et al.
• Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

• Authors: CIL, Ibrahim, et al.
• Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

• Authors: HIZAL, Mutlu, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
• Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
• Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

• Authors: DEMIR, Semra, et al.
• Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

• Authors: ÖZDEMIR, Seçil Kepil, et al.
• Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

• Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
• Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

• Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
• Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
• Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
• Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

• Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
• Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

• Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
• Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

• Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
• Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

• Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
• Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

• Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
• Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

• Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

• Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

• Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

• Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

• Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

• Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

• Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

• Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

Gastroenterology

Pendik Medipol University Hospital

Education

1999 Karadeniz Technical University, Gastroenterology

1997Atatürk University, Internal Diseases Professorship

1992 Atatürk University, Internal Diseases Associated Professorship 

1985 Atatürk University, Internal Diseases Specialist 

1981 Atatürk University Faculty of Medicine

Publications

1- Nihat Okçu Gülçin Polat,Arif Yılmaz,Mehmet Koruk,The demographıc features of gastrıc cancers ın erzurum(Eurasian J Med 2000; 32: 63-65)

2- Üst Gastrointestinal Kanamalı Olguların Bir Değerlendirilmesi. Klinik Bilimler-Doktor.2000, - E.akarsu,N.Okçu, ve Ark.Kuzeydoğu Anadolu’da 6:4:435-438

3-N.Okçu, A.yılmaz. İ.kiki,M.D.onuk, C.gündoğdu, H.uzunismail. Tanısal Üst Gastrointestinal endoskopi Sonuçlarımız. Atatürk Üniversitesi Tıp Dergisi 1997,29 (2):486

4-N. Okçu, M.gündoğdu, M.D. onuk, İ.kiki, l.cerrahoğlu, k.yılmaz, i. çapoğlu. Nonsteroid Anti İnflamatuar İlaç (NSAİİ) Kullanan Hastalarda oluşan Gastroduodenal Lezyonların Önlenmesinde Misoprostolün Yeri. Atatürk Üniversitesi Tıp Dergisi 1997,29 (2):453-455.

5-N.Okçu, A. öz, m.d. onuk, e.akarsu, b. tekin, h.z. tonbul, h.kaya. Kronik Aktif Hepatit İle Dekopanse Karaciğer Parankim Yetmezliğinde Plazma Fibronektin Düzeyleri ve Karaciğerin Fonksiyon Durumu İle İlişkisi. Türk J. Gastroenterol 1995;27(4): 422-426.

6-N.Okçu, tahir buran,m.d. onuk,a. yılmaz, e.akarsu, g. akçay. Erzurum ve Çevresinde Duodenum Ülserli Hastalarda Helicobacter Pylori Prevelansı. Türk J. Gastroenterol 1995;27(4): 447-450.

7-N.Okçu, b.s. uyanık, e. akarsu, e. bakan, z. tonbul. Mide ve Kolorektal Kanserlerinde Karbonhidrat Antijenleri (CA-19-9, CA-125), Karsinoembriyonik Antijen (CEA) ve Alkalen Fosfatazın Önemi. Türk J. Gastroenterol 1995;6:467-471.

8-N. Okçu, m.d. onuk, e. akarsu, h. doğan, c. gündoğdu. Bölgemizdeki Hepatoselüler Karsinomlu Hastalarda Major Risk Faktörleri. Gastroenteroloji 1994;5(2):154-157

9-N.Okçu, m.d. onuk, e. akarsu, h. doğan, c.gündoğdu, tahir buran. Erzurum Bölgesinde Gastrik Karsinom Sıklığı, Endoskopik ce Histolojik Özellikler. Gastroenteroloji 1994;5(2):263-267.

10-N. Okçu, m.d. onuk, tahir buran, e. akarsu, m.a. çiftçioğlu. Erzurum İli Çevresinde Nonspesifik Gastritli Olgularda Helicobacter Pylori Sıklığı. Gastroenteroloji 1994;5(2):211-213.

11-N.Okçu, m.d. onuk, ö. ünal, e. akarsu, l. incesu, k. akgöz. Karın İçi Kitle Lezyonlarında Ultrason Rehberliğinde Yapılan İnce İğne Aspirasyon Biyopsisinin Tanı Değeri. Gastroenteroloji 1993;4(1):166-68.

12-N.O.kçu, m.d. onuk, m. polat, a. yılmaz, m. gündoğdu, m. paç. Budd-Chiari Sendromu (2 Olgu). Türk J Gastroenterhepatol 1993; 4(1):77-80.

13-N.Okçu, h. koçak, m.d. onuk, m. gündoğdu, e. bakan, a. yılmaz, a. başoğlu, a. ateş, f.a. paç. The Effect of Atrial Pressure Changes and Cardiac Nerves on Plasma Atrial Natriüretic Peptide (ANP) Levels. Vascular Surgery 1993; 27(2): 128-132

15-N.Okçu, m.d. onuk, a.yılmaz, m. gündoğdu, t. buran. Omeprozol ve Ranitidinin Peptik Ülser İyileşmesine Etkileri. Doğa-Tr.J. of Medical Sciences 1992;16:657-658.

16-N. Okçu, m.r. yiğitoğlu, b. adam, e. bakan. Konjestif Kalp Yetersizliği Olan Hastalarda Digıxin’in Plazma Atrial Natriüretik Peptik Düzeyine Etkisi. S.Ü. Tıp Fak. Dergisi 1991;7(2):243-247..

17-N.Okçu, a. yılmaz. Üst Gastrointestinal Sistem Kanamalarında Histamin H2 -Reseptör Antagonistlerinin Etkisi. Endoskopi Dergisi 1991;2(4):17-23.

18-N.Okçu, E. bakan, b. adam, a. yılmaz, m.r. yiğitoğlu. Kronik Hepatit ve Karaciğer Sirozlu Hastalarda Seks Hormanları ve Seks Hormon Bağlayıcı Globülin Seviyeleri (Editöre Mektup). Doğa-Tr. J. Of Medical Sciences 1991;15:1-2.

19-N.Okcu Ömer Yılmaz.Helıcobacter pylorı and related gastroıntestınal system dıseases Turkiye Klinikleri JMed Sci. 2013;33(3):806-13

20-Nihat Okçu , Ömer yılmaz, hakan dursun, gülçin polat. Dispeptik semptomlarla beslenme alışkanlıkları, endoskopik ve histolojik bulgular arasındaki ilişki (Eurasian J Med 2006; 38: 13-17)

21-Mehmet Bilici,1Nihat Okcu,1Kerim Cayır,1Ibrahim Pirim,2Salim B. Tekin,1andCemal Gundogdu3 - Distribuion of HLA Tissue Groups in Patients with Gastric Cancer Eurasian J Med. 2010 Apr; 42(1): 9.11.

22-Nihat Okcu,Abdulhalim Bak,Mehmet Sari,Mehmet Arslan,Sait Kapicioglu :The fibroblast proliferation,relationship of hepatocyte growth factor (HGF) and interferon-A2A Gastroenterology April 2000Volume 118,Issue 4, Part 2, PageA1404

23-Kubra Kaynar,Sait Kapicioglu,Mehmet Sarı,Nihat Okcu,Abdulhalim Baki. The effect of fish oil on stress ulcer prophylaxis GastroenterologyVolume 118, Issue 4, Part 2, PageA1255

El Dr. Vladimir Yutkin es un médico altamente calificado del Centro Médico Hadassah con más de 20 años de experiencia en el diagnóstico y tratamiento de cánceres urológicos y director del Departamento de Oncología Urológica. Se graduó de la Universidad Hebrea de Jerusalén en 1996 y habla inglés, hebreo y ruso.

Oncólogo radioterápico licenciado con 8 años de formación médica, incluidos estudios de pregrado en la Facultad de Medicina de la Universidad de Marmara (2004-2011) y formación de especialización en Oncología Radioterápica en la Facultad de Medicina de la Universidad de Marmara (2012-2016). Educación previa de la escuela secundaria Sixteen Numbered Shirvan School (Azerbaiyán) (1998-2004).

El Dr. Raj es un oncólogo quirúrgico altamente experimentado con 19 años de experiencia y más de 50,000 cirugías de cáncer realizadas. Está involucrado en numerosos ensayos clínicos y tiene muchas publicaciones internacionales y nacionales en su haber. Se especializa en Oncología Quirúrgica Torácica y de Mama y se desempeña como profesor de Oncología Quirúrgica de Superespecialidad DNB y Cirugía de Mama en la Universidad de Ciencias de la Salud de Maharashtra. Su creencia es "agregar vida a los años" y mejorar la calidad de vida, no solo agregar años a la vida.

Prof. M.D. Yusuf Serdar Sakin was born in Nevşehir in 1978. After completing his primary and secondary education in Ankara, he graduated from the Faculty of Medicine at Gülhane Military Medical Academy in 2002.
Following his graduation, he served in Gole/Ardahan for two years. He started his internal medicine training at the Department of Internal Medicine, Gülhane Faculty of Medicine.
After completing his training, he worked as an internal medicine specialist in Ankara. A year later, he began additional training in the Department of Gastroenterology at Gülhane Faculty of Medicine and completed his training in 2014.
After graduation, Yusuf Serdar Sakin continued to work in the same department. He also received advanced endoscopy and Motility training at AMC Center in the Netherlands in 2017.
After obtaining the title of Associate Professor in 2017, he became a Professor in 2023.
He currently provides medical services to patients at Koru Ankara Hospital. His areas of medical interest include:

-Endoscopic retrograde cholangiopancreatography (ERCP)
-Push enteroscopy
-Endoscopic mucosal resection
-High-resolution manometry
-pH/pH-impedance metry analysis
-Advanced endoscopic procedures (stenting, dilation, etc.)
-Gastrointestinal motility disorders
-Gastroesophageal reflux disease
-Inflammatory bowel diseases
-Advanced endoscopic procedures and pancreatitis.

El Dr. Mouhamed Mounier Alwaw es Médico Gastroenterólogo con más de 12 años de experiencia, especializado en el tratamiento de enfermedades del tracto biliar y pancreático, detección temprana de cáncer de colon, hemostasia de hemorragias internas y tratamiento de la obesidad con balón gástrico. Tiene títulos de MBBS, MD y posgrado de Siria y París, y domina bien el árabe, el francés y el inglés. Tiene numerosas publicaciones, ensayos y presentaciones internacionales, así como varios programas de investigación sobre la disminución de las complicaciones posteriores a la CPRE y la enfermedad celíaca y el cáncer de colon.

El Dr. Alrawi es un oncólogo quirúrgico altamente calificado y experimentado certificado por la Junta con experiencia en oncología gastrointestinal superior, cabeza y cuello, mínimamente invasiva, mama, colorrectal y quimioperfusión calentada. Ha ocupado puestos en centros oncológicos de referencia terciarios y actualmente es el Director de Servicios de Oncología en el sistema hospitalario VPS en los EAU y MENA. También está involucrado en la investigación oncológica.

Especialista en Oncología Médica con experiencia en cáncer de pulmón, mama, colorrectal, gástrico, hígado, riñón, páncreas, estómago, próstata y útero. Experiencia en quimioterapia, inmunoterapia, fitoterapia, ozonoterapia, quimioterapia hipertérmica, cáncer GIS y cáncer ginecológico y genitourinario. Miembro del Grupo Turco de Oncología, Asociación de Oncología Médica, Asociación Turca de Investigación y Guerra del Cáncer, Sociedad Europea de Oncología Médica, Sociedad Europea de Oncología Ginecológica y Asociación Internacional para el Estudio del Cáncer de Pulmón.